These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30624000)

  • 1. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
    Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H
    J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study.
    Dong XQ; Wu Z; Li J; Wang GQ; Zhao H;
    J Gastroenterol Hepatol; 2019 Apr; 34(4):755-763. PubMed ID: 30290019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy.
    Liu T; Sun Y; Zhou J; Yang F; Zou X; Wang L; Wu X; Chen Y; Piao H; Lu L; Jiang W; Xu Y; Feng B; Nan Y; Xie W; Chen G; Zheng H; Li H; Ding H; Liu H; Wang T; Ou X; Wu S; Kong Y; Wang P; Cong M; Zhang Y; You H; Jia J
    J Med Virol; 2019 Aug; 91(8):1499-1509. PubMed ID: 30905065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
    Sun YM; Zhou JL; Wang L; Wu XN; Chen YP; Piao HX; Lu LG; Jiang W; Xu YQ; Feng B; Nan YM; Xie W; Chen GF; Zheng HW; Li H; Ding HG; Liu H; Lyu FD; Shao C; Wang TL; Ou XJ; Wang BQ; Chen SY; You H; Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):819-826. PubMed ID: 29325275
    [No Abstract]   [Full Text] [Related]  

  • 7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment.
    Wu SD; Liu LL; Cheng JL; Liu Y; Cheng LS; Wang SQ; Ma W; Chen LP; Tseng YJ; Wang JY; Shen XZ; Jiang W
    Clin Exp Med; 2018 Aug; 18(3):433-443. PubMed ID: 29696462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
    Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
    Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis.
    Wang L; Wang B; You H; Wu X; Zhou J; Ou X; Jia J
    Hepatol Int; 2018 May; 12(3):237-243. PubMed ID: 29700765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.
    Ji D; Chen Y; Shang Q; Liu H; Tan L; Wang J; Chen Y; Li Q; Long Q; Song L; Jiang L; Xiao G; Yu Z; Chen L; Hu X; Wang X; Chen D; Li Z; Dong Z; Chen G; Yang Y
    Am J Gastroenterol; 2021 Aug; 116(8):1676-1685. PubMed ID: 33840727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of liver stiffness measured by FibroTouch and FibroScan with Ishak fibrosis score in patients with chronic hepatitis B].
    Chen GF; Ping J; Gu HT; Zhao ZM; Zhou Y; Xing F; Tao YY; Mu YP; Liu P; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):145-150. PubMed ID: 28297803
    [No Abstract]   [Full Text] [Related]  

  • 13. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.
    Kuo YH; Lu SN; Chen CH; Chang KC; Hung CH; Tai WC; Tsai MC; Tseng PL; Hu TH; Wang JH
    PLoS One; 2014; 9(3):e93160. PubMed ID: 24682088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.
    Lim SG; Cho SW; Lee YC; Jeon SJ; Lee MH; Cho YJ; Kim SS; Kim YB; Seok JY; Cheong JY; Kim JH
    Hepatogastroenterology; 2011; 58(106):539-45. PubMed ID: 21661428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study.
    Liang X; Xie Q; Tan D; Ning Q; Niu J; Bai X; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Chen Y; Fan R; Sun J; Jia J; Hou J
    J Viral Hepat; 2018 Mar; 25(3):296-305. PubMed ID: 29080299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
    Wong GL; Wong VW; Choi PC; Chan AW; Chim AM; Yiu KK; Chu SH; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2011; 16(2):165-72. PubMed ID: 21447865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
    Çerçioğlu D; Kınıklı S; Cesur S; Ataman Hatipoğlu Ç; Arslan K; Gönültaş M
    Mikrobiyol Bul; 2020 Jan; 54(1):95-109. PubMed ID: 32050881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
    Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
    World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
    Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis.
    Isgro G; Calvaruso V; Andreana L; Luong TV; Garcovich M; Manousou P; Alibrandi A; Maimone S; Marelli L; Davies N; Patch D; Dhillon AP; Burroughs AK
    J Gastroenterol; 2013 Aug; 48(8):921-9. PubMed ID: 23124603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.